• English
    X

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Maryland Department of Health
    Genetics

    ​Provider’s Guide to Newborn Metabolic Screening Disorders

    The state of Maryland screens for over 50 disorders including endocrine, hematologic, and metabolic disorders. Maryland recommends two newborn screens; the first should be collected after 24 hours of feeding and the second after 7 days of life. About 10% of congenital hypothyroidism is missed on the initial screen but is picked up by the subsequent screen. The second screen picks up several children each year with conditions that are not detectable on the initial screen and, therefore, is vital to our newborn screening program.  In order to maximize optimal outcomes for infants identified on the second screen, the recommended timeframe for collection of the second screen has been changed from 1-4 weeks to 10-14 days of age, but specimens can be collected as early as 7 days of age. 
     
    The timing for collection of the Newborn Screen differs for babies in the NICU. All babies admitted to the NICU should have a Newborn Screen collected as soon as possible after admission so the baby is screened prior to transfusion and initiation of antibiotics. Additional screens should be collected between 2-3 days of age, at the 10 day interval, and then again at 1 month or discharge (whichever comes first).
     
    If your patient has an abnormal result that requires follow-up, the newborn screening follow-up team will call you and will work with you to create an appropriate follow-up plan for each baby.  Remember that every baby is different, so recommendations for follow-up of a particular abnormality may vary depending on circumstances; however, the links below can serve as a guideline for general disorder information.

    updated 07/2019